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Background: Early new ischemic lesions are common in patients with an acute isch-
emic stroke. These new ischemic lesions may represent the natural course of the initial 
stroke or de novo events.
Objective: We hypothesized that early new ischemic lesions located outside the initially 
affected vascular territory would point at de novo events. Therefore, we differentiated 
new ischemic lesions located outside the initially affected vascular territory from those 
occurring only inside the initially affected vascular territory to identify risk factors that are 
associated with de novo events.
Methods: Stroke patients underwent three magnetic resonance imaging examina-
tions (at 3-T): on admission, on the next day and 4–7 days after symptom onset 
(clinicaltrials.gov: NCT00715533). Diffusion-weighted imaging (DWI) lesions were 
delineated, coregistered, and then analyzed for new hyperintensities on follow-up 
examinations by raters blinded to clinical details. Patients were classified as having 
“new distant lesions” if new DWI lesions appeared outside or both outside and 
inside the initially affected vascular territory or “new local lesions” if they were only 
inside.
results: 115 patients with early new DWI lesions constitute the study population. 
Sixteen patients (14%) had new distant lesions and 99 patients (86%) had new local 
lesions. In comparison between patients with new distant and new local lesions, patients 
with new distant lesions had significantly more often elevated glycated hemoglobin 
(HbA1c ≥ 6.5%; p = 0.022).
conclusion: Our data indicate that patients with elevated HbA1c have an increased risk 
for new, de novo ischemic lesions in the acute phase after an ischemic stroke.
Keywords: stroke, diabetes mellitus, hemoglobin a, glycosylated, magnetic resonance imaging, new ischemic 
lesions, diffusion magnetic resonance imaging
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inTrODUcTiOn
Early new ischemic lesions are common in the acute phase after 
an ischemic stroke. Studies using serial magnetic resonance 
imaging (MRI) within 1  week after an initial ischemic stroke 
found that new lesions on diffusion-weighted imaging (DWI) 
appear in >30% of all patients. Most of the patients with these 
new ischemic lesions lack new clinically overt symptoms (silent 
strokes) (1–5). However, stroke patients with early new ischemic 
lesions are at an increased risk for subsequent clinically overt 
ischemic events (6).
Early new ischemic lesions in the acute phase after an 
ischemic stroke may represent different pathophysiological 
entities. Previously, it has been suggested that in patients with 
a (spontaneous or post-thrombolytic) vessel recanalization, new 
lesions may result from incomplete clot dissolution and distal 
embolization. These new lesions are directly related to the initial 
ischemic event and therefore represent the natural course of 
the disease (2–4, 7). By contrast, the occurrence of new lesions 
located outside the initially affected vascular territory cannot 
be explained by incomplete clot dissolution of the embolus. 
Therefore, we hypothesized that these new lesions represent de 
novo events (possibly originating from a proximal source such as 
the aortic arch or heart).
In this study, we investigated factors associated with the 
occurrence of new DWI lesions in relation to the initially 
affected vascular territory [defined as the territory of the left 
internal carotid artery (anterior left), the right internal carotid 
artery (anterior right), and the vertebrobasilar circulation 




Patients were included in this study as part of an observational 
study (1000Plus) conducted by the Center for Stroke Research 
Berlin (CSB) at the Campus Benjamin Franklin of the Charité—
Universitätsmedizin Berlin (clinicaltrials.gov: NCT00715533). 
The study enrolled all patients with an acute ischemic stroke 
within the last 24 h who were eligible for MRI. Details of this 
study have been previously published (2–4, 9). Patients recruited 
between March 2008 and December 2010, with a complete set 
of three examinations within the first week after symptom onset 
and initial DWI lesion(s) were included in the analysis of this 
study. Patients with ischemic lesions in all three vascular ter-
ritories (anterior left, anterior right, and posterior) on first MRI 
examination were excluded from the analysis, as were patients 
who underwent endovascular interventions. All patients 
received standard stroke unit care. The study was approved by 
the local Ethics Committee of the Charité—Universitätsmedizin 
Berlin (EA4/026/08) and all patients gave written informed 
consent (2–4).
imaging Protocol
The examinations were performed on a 3-T MRI scanner (Tim 
Trio, Siemens Medical, Erlangen, Germany). DWI was acquired 
with 230 mm field-of-view, fifty 2.5 mm axial slices without extra 
gap, with 1 b = 0 and along 6 directions of b = 1,000 s/mm2, rep-
etition time/echo time = 7,600/93 ms, and an acquisition matrix 
of 192 ×  192. Other sequences included axial fluid-attenuated 
inversion recovery, T2*-weighted imaging, perfusion imaging, 
and three-dimensional time-of-flight MR angiography of the 
intracranial circulation. We conducted three MR examinations: 
on admission, on the following day, and 4–7 days after onset of 
symptoms (2–4, 9).
image analysis
DWI were pseudonymized and afterwards reviewed in random 
order by raters blinded to clinical information. Hyperintensities 
on initial DWI were delineated manually, coregistered to the 
DWI on second day, and resliced to 1 mm isotropic voxel size. 
Coregistered DWIs were analyzed visually for new hyperintensi-
ties separate from the index lesion through slice-by-slice com-
parison of the first and second, as well as the second and third 
DWI. In this study, all new diffusion hyperintensities regardless 
of size and ADC value were considered.
The initial pattern of infarction was assessed on the first DWI. 
We defined three vascular territories: the territory of the left 
internal carotid artery (anterior left), the right internal carotid 
artery (anterior right), and the vertebrobasilar circulation (pos-
terior) (8). The fetal type of posterior cerebral artery was taken 
into consideration. New DWI lesions were classified as being 
“new distant lesions” if they were either outside or both outside 
and inside the initially affected vascular territory. New DWI 
lesions were classified as “new local lesions” if they were inside 
the initially affected vascular territory (Figure 1).
clinical Data
Sociodemographic and laboratory data were collected from 
the medical records. Patients with a known medical history of 
diabetes mellitus or patients with pre-existing antidiabetic medi-
cation were defined as having a “history of diabetes mellitus.” 
In addition, we surveyed glycated hemoglobin (HbA1c; method: 
high performance liquid chromatography) in all patients on 
admission and used an HbA1c cut point of ≥6.5% as a diag-
nostic criteria for diabetes mellitus according to international 
guidelines (10). Symptomatic carotid stenosis was defined as 
stenosis >50% on color-coded duplex sonography or magnetic 
resonance angiography that explained any symptomatic lesion. 
Stroke subtype was classified according to Trial of Org 10172 
in Acute Stroke Treatment criteria after a review of the clinical 
and imaging information (11). All patients were assessed for 
stroke severity directly before the first MR examination and 
daily until the day of discharge by physicians certified to assess 
the National Institutes of Health Stroke Scale (NIHSS) (12). 
Secondary prevention measures were implemented according to 
current practice guidelines (13). All patients were assessed four 
times daily for new neurological symptoms by a stroke physician 
dedicated to stroke care and patients’ complaints were taken into 
account. At the time of follow-up clinical examination, physi-
cians were blinded to MRI results. A clinical stroke recurrence 
was defined as a functional deterioration in the neurological 
status clearly distinct from that of the index stroke, attributable 
FigUre 1 | Diffusion-weighted imaging (DWI) of four patients with new DWI lesions. New distant lesions, appearing on day 2 (a) and day 5 (B). New local lesions 
appearing on day 2 (c) and day 5 (D).
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to a different vascular territory or the new event was of a different 
stroke subtype (1, 2, 4).
statistics
Clinical and neuroradiological characteristics of patients were 
compared using chi-square test for nominal and categorical vari-
ables. Statistical significance was determined at an alpha level of 
0.05 (2–4). Statistical analyses were performed using SPSS 22.
resUlTs
Out of 340 patients examined, 130 patients had new DWI lesions. 
Fifteen patients had ischemic lesions in all three vascular ter-
ritories on first MRI examination and were excluded from this 
analysis. Therefore, 115 patients with new DWI lesions constitute 
the (main) study population [37% female, median age 72 years 
(IQR 66–79), median NIHSS 4 (IQR 2–8)]. Of these 115 patients, 
clinical stroke recurrence occurred in three patients within the 
TaBle 1 | Sociodemographic and clinical parameters: patients with new lesions 
inside and outside the initially effected vascular territory.





Sex (women) 38 (38.4%) 5 (31.3%) 0.584
Age (>70 years) 58 (58.6%) 11 (68.8%) 0.441
NIHSS (>3) 52 (52.5%) 9 (43.8%) 0.515
Hyperlipoproteinemia 45 (45.5%) 11 (68.8%) 0.084
History of diabetes mellitus 22 (22.2%) 6 (37.5%) 0.186
Arterial hypertension 80 (80.8%) 14 (87.5%) 0.520




 – Small vessel













CHD 15 (15.2%) 2 (12.2%) 0.782
PAOD (95/16 pat.) 9 (9.5%) 2 (12.5%) 0.708
Previous stroke 25 (25.3%) 3 (18.8%) 0.574
Symptomatic carotid stenosis 11 (11.1%) 2 (12.5%) 0.871
Thrombolysis 38 (38.4%) 5 (31.3%) 0.584
Vessel recanalization 34 (34.3%) 7 (43.8%) 0.466
Antiplated therapy within 48 h  
after stroke
94 (94.9%) 15 (93.8%) 0.841



















HbA1c (≥6.5%) (90/14 pat.) 15 (16.5%) 6 (42.9%) 0.022
NIHSS, National Institutes of Health Stroke Scale; CHD, coronary heart disease; PAOD, 
peripheral artery occlusive disease; LDL, low density lipoprotein; INR, international 
normalized ratio; TOAST, Trial of Org 10172 in Acute Stroke Treatment.
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first week (3%). Sixteen patients (14%) had new DWI lesions 
outside (or both outside and inside) the initially affected vascular 
territory (new distant lesions) and 99 patients (86%) had new 
DWI lesions inside the initially affected vascular territory (new 
local lesions). Patients with new distant lesions had significantly 
more often elevated glycated hemoglobin (HbA1c  ≥  6.5%, 
p = 0.022; Table 1).
In a further analysis, comparison between patients with new 
distant lesions (n = 16) and all other acute stroke patients (both 
with new local lesions and without new lesions; n = 324) con-
firmed that new distant lesions appear significantly more often 
in patients with elevated glycated hemoglobin (42.9 vs. 18.7%, 
p =  0.027; data were available in 14/16 and 283/324 patients, 
respectively).
Out of 28 patients with a “history of diabetes mellitus,” 
27 patients (96%) had diabetes mellitus type 2. In patients 
with new distant lesions, two patients had a medical interven-
tion to lower blood glucose and one patient had a medical 
intervention to lower blood pressure during the course of the 
study. No patient with new distant lesions had hypoglycemia 
during the course of the study (data were available in 14/16 
patients).
DiscUssiOn
For the first time, we found a significant association between 
elevated glycated hemoglobin (HbA1c ≥  6.5%) and early new 
ischemic lesions located outside the initially affected vascular 
territory in acute stroke patients. New ischemic lesions in the 
acute phase after stroke may represent different pathophysi-
ological entities, namely either the natural course of the initial 
stroke or de novo events (3, 5, 7). We hypothesized that early new 
ischemic lesions located outside the initially affected vascular ter-
ritory could be interpreted as de novo events. Previously, it was 
reported that new ischemic lesions after stroke are associated with 
subsequent clinically overt ischemic events (1–4, 6). Assuming 
that new ischemic lesions represent different pathophysiological 
entities, especially those patients with new, de novo ischemic 
lesions might be at an increased risk for subsequent clinically 
manifest strokes.
We found a significant association between early new ischemic 
lesions located outside the initially affected vascular territory 
(new distant lesions) and elevated HbA1c. Elevated HbA1c was 
found to be an independent predictor for worse neurological and 
functional outcome after stroke and to predict future ischemic 
strokes (14–16). Poor glycemic control leads to endothelial 
dysfunction, coagulative activation, and platelet hyper-reactivity 
(17). Our data indicate that patients with elevated HbA1c also 
have an increased risk for new, de novo ischemic lesions in the 
acute phase after an ischemic stroke.
Interestingly, new distant lesions did not appear significantly 
more often in patients with a known medical history of diabetes 
mellitus or in patients with pre-existing antidiabetic medication 
(“history of diabetes mellitus”), which may implicate that elevated 
HbA1c is more sensitive in detecting poor glycemic control than 
surveying the patients’ past medical history.
It might come as a surprise that there was no significant 
association between new distant lesions and atrial fibrillation. 
The time interval investigated in our study was 1 week only and 
studies on (clinically manifest) stroke recurrence typically report 
on considerably longer time intervals up to several years (18). 
New cardiac thrombus formation may not happen within such a 
short-time interval.
Limitations of this study have to be considered. First, this is a 
single-center post hoc analysis. Second, the number of patients 
with new distant lesions was too small for multiple testing. 
Therefore, we cannot exclude false positive results. Third, 
due to the single-center setup, results cannot be generalized 
easily. Fourth, because of ethical considerations, patients were 
only included in the absence of contraindications to MRI and 
after giving written informed consent, which entails selection 
bias to the disadvantage of more severely affected and aphasic 
patients.
In conclusion, elevated HbA1c (≥6.5%) is associated with 
new, de novo ischemic lesions in patients with an acute ischemic 
stroke. Future prospective studies with long-term follow-up of 
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stroke patients with elevated HbA1c and new ischemic lesions 
are necessary to confirm this novel finding.
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